- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07475949
Ukjent tidspunkt for innsettende slag reperfusjon uten avansert bildebehandling (UTOPIA)
Intravenøs tenekteplase for akutte iskemiske hjerneslag med ukjent tidspunkt for symptomdebut under ikke-kontrast CT-seleksjon: Et multikenter, prospektivt, randomisert, åpent merket, blindet endepunktstudie
The benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain. This randomized study aims to assess the efficacy and safety of intravenous tenecteplase following non-contrast CT screening for acute ischemic stroke with unknown time of onset.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
UTOPIA is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) trial that aims to assess the efficacy and safety of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, selected by non-contrast CT. The primary outcome is excellent outcome, as defined by a score of 0 or 1 on modified Rankin Scale (mRS) at 90 days.
Participants randomized to the intervention group will receive intravenous tenecteplase at 0.25 mg/kg with a maximum dose of 25 mg and standard medical treatment, and those randomized to the control group will receive standard medical treatment only, without intravenous thrombolysis.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Dong Pan, MD, PhD
- Telefonnummer: 86-156 2648 3251
- E-post: dongpan012@hotmail.com
Studiesteder
-
-
Fujian
-
Xiamen, Fujian, Kina, 361004
- Har ikke rekruttert ennå
- Zhongshan Hospital of Xiamen University
-
Ta kontakt med:
- Xingyu Chen
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510620
- Har ikke rekruttert ennå
- Guangzhou Twelfth People's Hospital
-
Ta kontakt med:
- Jianwu Dai
-
-
Guangxi
-
Baise City, Guangxi, Kina, 533000
- Har ikke rekruttert ennå
- Baise People's Hospital
-
Ta kontakt med:
- Dengxing Li
-
Chongzuo, Guangxi, Kina, 532200
- Rekruttering
- The People's Hospital of Chongzuo
-
Ta kontakt med:
- Jianyi Huang
-
Guigang, Guangxi, Kina, 537121
- Har ikke rekruttert ennå
- People's Hospital of Qintang District, Guigang City
-
Ta kontakt med:
- Jixin Lu
-
Guigang, Guangxi, Kina, 537200
- Har ikke rekruttert ennå
- Guiping People's Hospital
-
Ta kontakt med:
- Peiquan Yang
-
Laibin, Guangxi, Kina, 545900
- Har ikke rekruttert ennå
- Wuxuan County People's Hospital
-
Ta kontakt med:
- Yu Huang
-
Liuzhou, Guangxi, Kina, 545007
- Har ikke rekruttert ennå
- Liuzhou Workers' Hospital
-
Ta kontakt med:
- Liya Pan
-
Nanning, Guangxi, Kina, 530021
- Har ikke rekruttert ennå
- The First Affiliated Hospital of Guangxi Medical University
-
Ta kontakt med:
- Dong Pan, MD, PhD
- Telefonnummer: 86-156 2648 3251
- E-post: dongpan012@hotmail.com
-
Hovedetterforsker:
- Yuan Wu, MD, PhD
-
Nanning, Guangxi, Kina, 530200
- Har ikke rekruttert ennå
- Nanning Yongning District People's Hospital
-
Ta kontakt med:
- Wuqiao Liang
-
Ta kontakt med:
- Qihai Zhou
-
Nanning, Guangxi, Kina, 530219
- Har ikke rekruttert ennå
- Guangxi Medical University Kaiyuan Langdong Hospital
-
Ta kontakt med:
- Kai Chen
-
Nanning, Guangxi, Kina, 530409
- Har ikke rekruttert ennå
- No.9 People's Hospital of Nanning
-
Ta kontakt med:
- Jun Qu
-
Qinzhou, Guangxi, Kina, 535000
- Har ikke rekruttert ennå
- The Second People's Hospital of Qinzhou
-
Ta kontakt med:
- Caixia Xuan
-
-
Shaanxi
-
Yulin, Shaanxi, Kina, 718100
- Har ikke rekruttert ennå
- Mizhi County Hospital
-
Ta kontakt med:
- Tao Zhang
-
Yulin, Shaanxi, Kina, 718600
- Har ikke rekruttert ennå
- Dingbian County People's Hospital
-
Ta kontakt med:
- Gaiyan Qu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years old.
- Clinical diagnosis of acute ischemic stroke.
- Unknown time of stroke onset (e.g., stroke symptom recognized on awakening) but last-known normal time >4.5 hours.
- Time from stroke symptom recognition (e.g., awakening) to randomization within 3 hours.
- National Institutes of Health Stroke Scale (NIHSS) score of 6-25 (both inclusive).
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Written informed consent from patients or their legally authorized representatives.
Exclusion Criteria:
- Intracranial hemorrhage confirmed by skull CT, or history of intracranial hemorrhage.
- Planned endovascular treatment.
- Rapid neurological improvement with NIHSS <6 at randomization.
- Allergy to tenecteplase.
- Use of vitamin K antagonist with INR >1.7, use of heparin or low molecular heparin in the past 24 hours, or use of direct oral anticoagulants in the past 48 hours.
- Hypodensity on non-contrast CT >1/3 middle cerebral artery territory.
- Severe traumatic brain injury or other major trauma in the past 3 months.
- Intracranial neoplasm, arteriovenous malformation, or aneurysm (≥10mm).
- Intracranial surgery, intraspinal surgery, or other major surgery in the past 3 months.
- Gastrointestinal or urinary tract hemorrhage in the past 3 weeks.
- Active internal bleeding.
- Aortic dissection.
- Infective endocarditis.
- Platelet count <100×10^9/L.
- Women who are pregnant or breastfeeding.
- Blood glucose <50 or >400 mg/dL (<2.78 or >22.2 mmol/L).
- Systolic blood presure >185 mmHg or diastolic blood presure >110 mmHg refractory to treatment.
- Life expectancy <3 months.
- Participating in other trials.
- Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Control group
Standard Medical Treatment |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. |
|
Eksperimentell: Tenecteplase group
Intravenous tenecteplase thrombolysis |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Excellent outcome
Tidsramme: 90 (±14) days
|
The proportion of modified Rankin Scale (mRS) score of 0-1 at 90 days |
90 (±14) days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Level of disability
Tidsramme: 90 (±14) days
|
Ordinal shift analysis of the mRS with 5-6 merged at 90 days. |
90 (±14) days
|
|
Functional independence
Tidsramme: 90 (±14) days
|
The proportion of mRS score of 0-2 at 90 days. |
90 (±14) days
|
|
Early neurological improvement
Tidsramme: 24 (±12) hours
|
The proportion of NIHSS 0-1 or ≥4 points reduction at 24 (±12) hours. |
24 (±12) hours
|
|
Change in stroke severity
Tidsramme: 7 (±1) days or at discharge
|
The change of NIHSS score from baseline to 7 days or at discharge (whichever comes first) |
7 (±1) days or at discharge
|
|
Quality of life measured by EQ-5D-5L
Tidsramme: 90 (±14) days
|
EQ-5D-5L scale score at 90 days. |
90 (±14) days
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Symptomatic intracranial hemorrhage
Tidsramme: 24 (±12) hours
|
Incidence of symptomatic intracranial hemorrhage within 36 hours from randomization (Heidelberg criteria) |
24 (±12) hours
|
|
Any intracranial hemorrhage
Tidsramme: 24 (±12) hours
|
Incidence of any intracranial hemorrhage within 36 hours from randomization (Heidelberg classification) |
24 (±12) hours
|
|
Extracranial bleeding
Tidsramme: 24 (±12) hours
|
Incidence of moderate-to-severe extracranial bleeding (GUSTO criteria) within 36 hours from randomization |
24 (±12) hours
|
|
Mortality
Tidsramme: 90 days
|
All cause death within 90 days. |
90 days
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Yuan Wu, MD, PhD, First Affiliated Hospital of Guangxi Medical University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Cerebrovaskulære lidelser
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Slag
- Iskemisk hjerneslag
- Aminosyrer, peptider og proteiner
- Proteiner
- Hydrolaser
- Enzymer
- Enzymer og koenzymer
- Blodproteiner
- Endopeptidaser
- Peptidhydrolaser
- Serine endopeptidaser
- Serinproteaser
- Plasminogenaktivatorer
- Blodkoagulasjonsfaktorer
- Vevsplasminogenaktivator
- Tenecteplase
Andre studie-ID-numre
- 2026-K0237
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Data supporting the findings of the study are available on reasonable request after approval of a proposal from the principal investigator.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .